Novo Nordisk's Semaglutide Helps 40% of Obese Children Exit Obesity Threshold in Phase 3 Trial — Novo Nordisk

Event summary

Novo Nordisk's STEP Young phase 3 trial met its primary endpoint, showing 40.4% of children aged 6 to under 12 with obesity achieved a BMI below the obesity threshold after 68 weeks of semaglutide treatment.
The trial compared semaglutide with placebo, both combined with lifestyle modifications, with no children in the placebo group achieving a non-obese BMI.
Over 85% of participants had severe (class II or III) obesity at baseline, highlighting the trial's focus on high-need patients.
Safety and tolerability of semaglutide were consistent with previous trials, with no new concerns identified for growth or pubertal development.

The big picture

Novo Nordisk's STEP Young trial results position semaglutide as a potential breakthrough in pediatric obesity treatment, an area with limited approved therapies. The data underscores the growing global burden of childhood obesity, projected to rise to 228 million cases by 2040, and highlights Novo Nordisk's leadership in developing obesity medications. The success of this trial could expand the market for semaglutide beyond adult obesity, addressing a critical unmet need in younger patients.

What we're watching

Regulatory Approval: Whether Novo Nordisk can secure regulatory approval for semaglutide in pediatric obesity, given the positive phase 3 results.
Market Expansion: The pace at which Novo Nordisk can expand semaglutide's use in pediatric populations, potentially creating a new revenue stream.
Competitive Dynamics: How competitors like Eli Lilly respond to Novo Nordisk's success in pediatric obesity, particularly with their own GLP-1 agonists.